The historical rank and industry rank for Coherus BioSciences's FCF Margin % or its related term are showing as below:
CHRS'
s FCF Margin % Range Over the Past 10 Years
Min: -13165.75 Med: -86.08 Max: 30.88
Current: -68.09
During the past 12 years, the highest FCF Margin % of Coherus BioSciences was 30.88%. The lowest was -13165.75%. And the median was -86.08%.
CHRS's FCF Margin % is ranked better than 58.58% of 1031
companies
in the Biotechnology industry
Industry Median: -148.24
vs CHRS: -68.09
Coherus BioSciences FCF Margin % Historical Data
The historical data trend for Coherus BioSciences's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Coherus BioSciences's FCF Margin %
For the Biotechnology subindustry, Coherus BioSciences's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coherus BioSciences's FCF Margin % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Coherus BioSciences's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Coherus BioSciences's FCF Margin % falls into.
Coherus BioSciences FCF Margin % Calculation
FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.
Coherus BioSciences's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Coherus BioSciences FCF Margin % Related Terms
Thank you for viewing the detailed overview of Coherus BioSciences's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Coherus BioSciences (Coherus BioSciences) Business Description
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company is also developing CHS-305, a biosimilar of Avastin. The company generates revenue primarily from the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CHRS has been successfully added to your 